Medline Inc. filed an 8-K on November 18, 2026, disclosing a $200 million share and unit repurchase agreement with private equity selling stockholders and the concurrent pricing of a 60,000,000-share secondary offering.

Key Highlights

  • $200 million repurchase: Medline Inc. and Medline Holdings, LP agreed to repurchase an aggregate of $200 million of Class A common stock and Common Units directly from certain selling stockholders in a private, non-underwritten transaction.
  • Selling stockholders: The selling parties include entities affiliated with Blackstone Inc., The Carlyle Group Inc., and Hellman & Friedman LLC, along with GIC Private Limited and its managed affiliate and a wholly owned subsidiary of the Abu Dhabi Investment Authority.
  • Repurchase price: The price per equity interest in the repurchase equals the price paid by the underwriters in the concurrent secondary offering.
  • Secondary offering sized at 60 million shares: The company announced the pricing of an underwritten secondary offering of 60,000,000 shares of Class A common stock, expected to yield net proceeds to the selling stockholders of approximately $2.1 billion, excluding any exercise of the underwriters' 30-day option to purchase up to an additional 9,000,000 shares.
  • Expected closing date: The secondary offering is expected to close on November 23, 2026, subject to customary closing conditions; the repurchase is expected to close concurrently with the offering.
  • Audit Committee approval: The repurchase was approved by the Audit Committee of the company's Board of Directors, which the filing states "consists solely of independent directors," and counts toward the company's previously announced share repurchase program.
  • Class B stock cancellation: To the extent Common Units are repurchased, the corresponding selling stockholder will transfer an equivalent number of Class B common shares to the company for no additional consideration, and those shares will be cancelled and retired.

Medline's $200M Direct Repurchase and 60-Million-Share Secondary Offering Details

According to the filing, on November 16, 2026, Medline Inc. (NASDAQ:MDLN) and Medline Holdings, LP entered into a share and unit repurchase agreement with the selling stockholders. The company disclosed that each of the selling stockholders, other than the wholly owned subsidiary of the Abu Dhabi Investment Authority, "beneficially owns more than 5% of the Company's Class A common stock." The filing also notes that certain of the selling stockholders have various other relationships with the company, directing readers to the "Certain Relationships and Related Person Transactions" section of the company's proxy statement filed with the SEC on April 23, 2026.

The repurchase agreement is conditioned upon the closing of the secondary offering, though the filing states that "the closing of the Offering is not conditioned upon the closing of the Repurchase." The repurchase will count toward the company's previously announced share repurchase program, the filing noted. The Repurchase Agreement is attached as Exhibit 10.1 to the 8-K.

Separately, on November 17, 2026, the company issued a press release announcing the pricing of the underwritten secondary offering of 60,000,000 shares. The filing notes that the shares in the offering were offered solely by the selling stockholders, with net proceeds going to those parties rather than to Medline Inc. itself. The underwriters hold a 30-day option to purchase up to an additional 9,000,000 shares.

What Was Disclosed

Medline Inc. disclosed a $200 million private repurchase agreement with affiliated private equity selling stockholders, concurrent with a 60,000,000-share secondary offering priced on November 17, 2026, and expected to close November 23, 2026. The 8-K was signed by Chief Financial Officer Michael B. Drazin.